Document is current

Article History

Received: 18 June 2024

Accepted: 23 August 2024

First Online: 14 December 2024

Declarations

:

: Anat Loewenstein: Consultant: 4DMT, AbbVie, Alkeus, Annexon, Apellis, Astellas, Bayer Health Care, Beyeonics, Eyepoint, Johnson & Johnson, NotalVision, Novartis, Ocular Therapeutics, Oculis, Ocuphire Pharma, Ocuterra, Opthea, Oxurion, Roche, Syneos; Michelle Sylvanowicz: Employee: Bayer; Winfried M. Amoaku: Advisory board membership: AbbVie, Alcon, Alimera, Allergan, Apellis, Bayer, Bausch + Lomb, Bioeq, Novartis, Pfizer; Speaker fees: Alimera, Allergan, Bayer, Novartis, Pfizer; Support for travel: Alimera, Allergan, Bayer, Novartis, Pfizer; Research sponsorship and funding: Allergan, Bayer, Boehringer Ingelheim, CenterVue, Gyroscope, Novartis, Optos; Tariq Aslam: Tariq Aslam is an Editor in Chief of <i>Ophthalmology and Therapy</i>, and was not involved in the selection of peer reviewers for the manuscript nor any subsequent editorial decisions. Consultant: Novartis, Bayer, Laboratoires, Théa Pharmaceuticals, Bausch & Lomb, Oraya; Chui Ming Gemmy Cheung: Financial support (to institution): Allergan, Bayer, Boehringer Ingelheim, Novartis, Roche, Topcon, Zeiss; Stock: Avirmax; Bora Eldem: Consultant: Allergan, Bayer, Novartis, Roche; Robert P. Finger: Research grant: CentreVue, Heidelberg Engineering, Novartis, Zeiss; Consultant: Alimera, Allergan, Bayer, Ellex, Inositec, Novartis, Opthea, Roche/Genentech, Santhera; Support for travel: Novartis; Richard P. Gale: Consultant/advisory boards: Allergan, Alimera, Bayer, Novartis, Santen; Educational travel grants: Allergan, Bayer, Heidelberg, Novartis; Research grants: Allergan, Bayer, Novartis, Roche; Laurent Kodjikian: Consultant: AbbVie, Alcon, Allergan, Bayer, Krystal Biotech, Novartis, Regeneron, Théa; Adrian Koh: Consultant: Allergan, Bayer, Carl Zeiss, Heidelberg, Novartis, Topcon; Jean-François Korobelnik: Consultant: AbbVie, Apellis, Bayer, Eyepoint Pharma, Ocuphire, Roche, Thea, Carl Zeiss Meditec; Member of DSMB for Alexion, Novo Nordisk, Opthea; Xiaofeng Lin: Consultant: Bayer; Paul Mitchell: Consultant: Allergan, Bayer, Novartis; Steering Committee member: Bayer; Moira Murphy: Employee: Exploristics, Ltd.; Mali Okada: Non-financial support and personal fees: Bayer; Ian Pearce: Lecture fees: Allergan, Bayer, Heidelberg, Novartis; Consultant: Allergan, Alimera, Bayer, Novartis; Support for travel: Allergan, Bayer, Novartis; Francisco J. Rodriguez: Consultant: Bayer, Novartis, Roche; Speaker: Bayer, Novartis, Roche; Research funding: Novartis; Jude Stern: Employee: The International Agency for the Prevention of Blindness; S. James Talks: Advisory board member, speaker fees, and research support: Bayer, Novartis; research grants: Boehringer Ingelheim, Roche; Consultant: Bayer; David T. Wong: Grants/research support: Bayer, Novartis, Roche; Consultant: Alcon, Allergan, Bausch Health, Bayer, Novartis, Topcon, Zeiss; Equity: Arctic DX; Tien Yin Wong: Clinical trial grants: Allergan, Bayer, Boehringer Ingelheim, Genentech, Merck, Novartis, Oxurion (formerly ThromboGenics), Roche, Samsung Bioepis, NMRC Singapore, Novartis Singapore; Consulting fees/travel support/review fees: Allergan, Bayer, Boehringer Ingelheim, Genentech, Merck, Novartis, Oxurion (formerly ThromboGenics), Roche, Samsung Bioepis; Stock: EyRIS, Plano; Focke Ziemssen: Travel grants and personal fees: Allergan, Alimera, Bayer Healthcare, Biogen, Boehringer Ingelheim, Clearside, Novartis, Novo Nordisk, MSD Sharp & Dohme, Roche, Optos; Jane Barratt: Consultant: Bayer.

: The survey was designed and developed according to the Declaration of Helsinki and the World Health Organization’s International Ethical Guidelines for Biomedical Research. While the survey is a Primary Market Research Survey (which does not require ethics committee approval), individual institutions and countries assessed local requirements. Furthermore, informed consent was acquired, no personally identifiable information was collected, and treatment decisions were not informed by response to the survey.